The American Journal of Cardiology ® | October 20-25, 2007 | TCT Abstracts/ELECTRONIC 181L ELECTRONIC ABSTRACTS http://www.aievolution.com/tct0701/ Interventional Pharmacology Saturday, October 20, 2007 (Abstract Nos. 463-464) TCT-463 Platelet Inhibition And Myocardial Necrosis In Elective Coronary Artery Stenting Andrew Wiper 1 , R Anantharaman 1 , M Schmitt 1 , M Brack 1 , A Chauhan 1 , S Eccleshall 1 , G Goode 1 , R More 1 , M Pirmohamed 2 , J Quinn 1 , D H Roberts 1 1 Lancashire Cardiac Centre, Blackpool, United Kingdom 2 University of Liverpool, Liverpool, United Kingdom Background: Suboptimal antiplatelet therapy has been implied in the abciximab in acute coronary syndrome is well recognised. However, the role of this therapy in ePCI is unclear. We sought to determine any correlation between peri-procedural platelet inhibition and MN in ePCI. Methods: 88 patients undergoing ePCI were randomised to receive either Clopidogrel 600mg (Group 1) or Clopidogrel 300mg + peri-procedural abciximab (Group 2). Platelet function was evaluated ex vivo by both optical aggregometry (BDFacsCalibur). Results difference in enzyme release pattern between the groups. Importantly, there was no correlation between peri-procedural enzyme release and peri- procedural platelet inhibition. Figure 1 illustrates platelet inhibition on the y- Conclusion: The degree of peri-procedural MN appears unrelated to the degree of peri-procedural platelet inhibition. High dose clopidogrel is non- saving implications. TCT-464 Relationship Between Improvement in Serum ApoB/ApoA1 Ratio and Progression-regression of Coronary Artery Plaque with HMG-CoA Reductase Inhibitors (statins): A Three-dimensional Intravascular Ultrasound (3D-IVUS) Study Hiroaki Takashima 1 , Katsuhisa Waseda 2 , Yoshinori Wakita 1 , Kenji Asai 1 , Yasuo Kuroda 1 , Takashi Kosaka 1 , Yasushi Kuhara 1 , Tomofumi Mizuno 1 , Akiyoshi Kurita 1 , Kazuyuki Maeda 1 , Hirokazu Wakabayashi 1 , Tatsuya Yasukawa 3 , Takayuki Ito 1 1 Department of Cardiology, Aichi Medical University School of Medicine, Nagakute, Japan 2 Center for Research in Cardiovascular Interventions, Stanford University, Stanford, CA; 3 Yasukawa Clinic, Nagoya, Japan Background: Serum ApoB/ApoA1 ratio has been reported to be an independent risk factor of coronary artery disease. Moreover, there have been many reports that hypolipidemic therapy with statins contributes to suppression of coronary artery plaque progression. However, there have been few reports of IVUS to investigate the correlation between serum ApoB/ApoA1 ratio and progression of coronary artery plaque during statin administration. Methods: Serial IVUS analyses (post-PCI and average 8 months follow-up) were available in 66 patients. Lipid data including serum ApoA1 and ApoB were examined at post-PCI and follow-up. Pitavastatin (2 mg/daily) was prescribed in 39 patients. The left main coronary artery, which was not involved in PCI, was chosen for this IVUS analysis. Volume index (VI: volume/length) was obtained for vessel (VVI), lumen (LVI) and plaque (PVI). Results: pitavastatin administration. While negative correlation was observed between % change of serum ApoB/ApoA1 and % change of LVI (y=-2.9148 -0.2181x, r=-0.363, p=0.0028), a positive correlation was observed between % change of serum ApoB/ApoA1 and % change of PVI (y=1.2897 +0.2604x, r=0.398, p=0.0009). Conclusion: These IVUS results showed a correlation between serum ApoB/ ApoA1 ratio and progression of coronary artery plaque. Thus, a decrease in serum ApoB/ApoA1 ratio as a result of pitavastatin may suppress the progression of coronary artery plaque.

Interventional Pharmacology (E-Poster 463-464)

Download PDF Report

View
217
Download
0

Embed Size (px)

Citation preview

Page 1: Interventional Pharmacology (E-Poster 463-464)

The American Journal of Cardiology® | October 20-25, 2007 | TCT Abstracts/ELECTRONIC 181L

IC A

http://www.aievolution.com/tct0701/

Interventional Pharmacology

Saturday, October 20, 2007

(Abstract Nos. 463-464)

TCT-463

Platelet Inhibition And Myocardial Necrosis In Elective Coronary Artery Stenting

Andrew Wiper1, R Anantharaman1, M Schmitt1, M Brack1, A Chauhan1, S Eccleshall1, G Goode1, R More1, M Pirmohamed2, J Quinn1, D H Roberts1 1Lancashire Cardiac Centre, Blackpool, United Kingdom2University of Liverpool, Liverpool, United Kingdom

Background: Suboptimal antiplatelet therapy has been implied in the

abciximab in acute coronary syndrome is well recognised. However, the role of this therapy in ePCI is unclear. We sought to determine any correlation between peri-procedural platelet inhibition and MN in ePCI.Methods: 88 patients undergoing ePCI were randomised to receive either Clopidogrel 600mg (Group 1) or Clopidogrel 300mg + peri-procedural abciximab (Group 2).Platelet function was evaluated ex vivo by both optical aggregometry

(BDFacsCalibur).Results

difference in enzyme release pattern between the groups. Importantly, there was no correlation between peri-procedural enzyme release and peri-procedural platelet inhibition. Figure 1 illustrates platelet inhibition on the y-

Conclusion: The degree of peri-procedural MN appears unrelated to the degree of peri-procedural platelet inhibition. High dose clopidogrel is non-

saving implications.

TCT-464

Relationship Between Improvement in Serum ApoB/ApoA1 Ratio and Progression-regression of Coronary Artery Plaque with HMG-CoA Reductase Inhibitors (statins): A Three-dimensional Intravascular Ultrasound (3D-IVUS) Study

Hiroaki Takashima1, Katsuhisa Waseda2, Yoshinori Wakita1, Kenji Asai1, Yasuo Kuroda1, Takashi Kosaka1, Yasushi Kuhara1, Tomofumi Mizuno1, Akiyoshi Kurita1, Kazuyuki Maeda1, Hirokazu Wakabayashi1, Tatsuya Yasukawa3, Takayuki Ito1 1Department of Cardiology, Aichi Medical University School of

Medicine, Nagakute, Japan2Center for Research in Cardiovascular Interventions, Stanford University, Stanford, CA;3Yasukawa Clinic, Nagoya, Japan

Background: Serum ApoB/ApoA1 ratio has been reported to be an independent risk factor of coronary artery disease. Moreover, there have been many reports that hypolipidemic therapy with statins contributes to suppression of coronary artery plaque progression. However, there have been few reports of IVUS to investigate the correlation between serum ApoB/ApoA1 ratio and progression of coronary artery plaque during statin administration.Methods: Serial IVUS analyses (post-PCI and average 8 months follow-up) were available in 66 patients. Lipid data including serum ApoA1 and ApoB were examined at post-PCI and follow-up. Pitavastatin (2 mg/daily) was prescribed in 39 patients. The left main coronary artery, which was not involved in PCI, was chosen for this IVUS analysis. Volume index (VI: volume/length) was obtained for vessel (VVI), lumen (LVI) and plaque (PVI).Results: pitavastatin administration. While negative correlation was observed between % change of serum ApoB/ApoA1 and % change of LVI (y=-2.9148 -0.2181x, r=-0.363, p=0.0028), a positive correlation was observed between % change of serum ApoB/ApoA1 and % change of PVI (y=1.2897 +0.2604x, r=0.398, p=0.0009).Conclusion: These IVUS results showed a correlation between serum ApoB/ApoA1 ratio and progression of coronary artery plaque. Thus, a decrease in serum ApoB/ApoA1 ratio as a result of pitavastatin may suppress the progression of coronary artery plaque.